Regulation (EC) No 141/2000 on orphan medicinal products

E546469

Regulation (EC) No 141/2000 on orphan medicinal products is a key European Union law that establishes incentives and a special approval framework to encourage the development and marketing of medicines for rare diseases.

Try in SPARQL Jump to: Surface forms Statements Referenced by

Observed surface forms (1)

Statements (47)

Predicate Object
instanceOf European Union regulation
orphan medicinal products legislation
adoptedBy Council of the European Union NERFINISHED
European Parliament NERFINISHED
adoptionYear 1999
aimsTo encourage development of medicines for rare diseases
ensure availability of treatments for patients with rare conditions
facilitate placing on the market of orphan medicinal products
appliesTo all EU Member States
human medicinal products
cameIntoForceYear 2000
criterionIncludes lack of sufficient return on investment without incentives
prevalence threshold for rare diseases in the EU
requirement of significant benefit over existing methods
defines concept of orphan medicinal product in the EU
criteria for orphan designation in the EU
rules for maintenance and withdrawal of orphan designation
rules for transfer of orphan designation
establishes 10-year market exclusivity for authorised orphan medicinal products
Committee for Orphan Medicinal Products NERFINISHED
Community register of orphan medicinal products NERFINISHED
conditions for reduction of market exclusivity period
procedure for orphan designation applications
rules on information exchange and transparency for orphan medicinal products
implementedBy Committee for Orphan Medicinal Products NERFINISHED
European Medicines Agency NERFINISHED
jurisdiction European Union
language all official languages of the European Union
legalBasisFor centralised procedure for orphan medicinal products in the EU
designation of orphan medicinal products in the EU
fee reductions for orphan medicinal products in the EU
incentives for development of orphan medicinal products
market exclusivity for orphan medicinal products in the EU
protocol assistance for orphan medicinal products in the EU
legalForm Regulation (EC) NERFINISHED
monitoredBy European Commission NERFINISHED
number 141/2000
policyArea pharmaceutical regulation
public health
rare disease policy
provides market exclusivity incentives for orphan medicinal products
regulatory fee reductions for orphan medicinal products
scientific advice incentives for orphan medicinal products
relatedTo EU pharmaceutical legislation NERFINISHED
centralised marketing authorisation procedure in the EU
subjectMatter orphan medicinal products
rare diseases

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

COMP usesLegalBasis Regulation (EC) No 141/2000 on orphan medicinal products
Orphan Drug Act of 1983 relatedTo Regulation (EC) No 141/2000 on orphan medicinal products
this entity surface form: European Union orphan medicinal product regulation